Phosphofructokinase P fine-tunes T regulatory cell metabolism, function, and stability in systemic autoimmunity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36449620.
- Also identified by DOI 10.1126/sciadv.adc9657 and PMC identifier 9710877.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by defective regulatory T (T<sub>reg</sub>) cells. Here, we demonstrate that a T cell-specific deletion of calcium/calmodulin-dependent protein kinase 4 (CaMK4) improves disease in B6.<i>lpr</i> lupus-prone mice and expands T<sub>reg</sub> cells. Mechanistically, CaMK4 phosphorylates the glycolysis rate-limiting enzyme 6-phosphofructokinase, platelet type (PFKP) and promotes aerobic glycolysis, while its end product fructose-1,6-biphosphate suppresses oxidative metabolism. In T<sub>reg</sub> cells, a CRISPR-Cas9-enabled <i>Pfkp</i> deletion recapitulated the metabolism of <i>Camk4</i><sup>-/-</sup> T<sub>reg</sub> cells and improved their function and stability in vitro and in vivo. In SLE CD4<sup>+</sup> T cells, PFKP enzymatic activity correlated with SLE disease activity and pharmacologic inhibition of CaMK4-normalized PFKP activity, leading to enhanced T<sub>reg</sub> cell function. In conclusion, we provide molecular insights in the defective metabolism and function of T<sub>reg</sub> cells in SLE and identify PFKP as a target to fine-tune T<sub>reg</sub> cell metabolism and thereby restore their function.
Medical subject headings
- Phosphofructokinases
- Lupus Erythematosus, Systemic